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Abstract The anti-estrogen tamoxifen is characterized by
a large variability in response, partly due to pharmacokinetic
differences. We examined circadian variation in tamoxifen
pharmacokinetics in mice and breast cancer patients. Phar-
macokinetic analysis was performed in mice, dosed at six
different times (24-h period). Tissue samples were used for
mRNA expression analysis of drug-metabolizing enzymes.
In patients, a cross-over study was performed. During three
24-h periods, after tamoxifen dosing at 8 a.m., 1 p.m., and 8
p.m., for at least 4 weeks, blood samples were collected for
pharmacokinetic measurements. Differences in tamoxifen
pharmacokinetics between administration times were
assessed. The mRNA expression of drug-metabolizing
enzymes showed circadian variation in mouse tissues.
Tamoxifen exposure seemed to be highest after adminis-
tration at midnight. In humans, marginal differences were
observed in pharmacokinetic parameters between morning
and evening administration. Tamoxifen Cmax and area under
the curve (AUC)0–8 h were 20 % higher (P\ 0.001), and
tamoxifen tmax was shorter (2.1 vs. 8.1 h; P = 0.001),
indicating variation in absorption. Systemic exposure
(AUC0–24 h) to endoxifen was 15 % higher (P\ 0.001)
following morning administration. The results suggest that
dosing time is of marginal influence on tamoxifen pharma-
cokinetics. Our study was not designed to detect potential
changes in clinical outcome or toxicity, based on a differ-
ence in the time of administration. Circadian rhythm may be
one of the many determinants of the interpatient and intra-
patient pharmacokinetic variability of tamoxifen.
Keywords Tamoxifen  Endocrine therapy  Breast
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Introduction
Tamoxifen belongs to the selective estrogen receptor
modulators, and has been used extensively in the treatment
of hormone receptor-positive breast cancer since its intro-
duction. The drug acts as an estrogen receptor antagonist in
breast tissue and has been shown to be beneficial in
reducing the risk of disease recurrence and breast cancer
mortality in the adjuvant setting as well as prolonging
survival in patients with metastatic disease [1, 2]. However,
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its use is characterized by large inter-individual variability
in response, and non-response is observed in 30–50 % of
the patients. One of the mechanisms that may underlie the
variable clinical response to tamoxifen is variability in
pharmacokinetics [1–3].
Tamoxifen is considered a pro-drug and undergoes
extensive biotransformation into various metabolites,
catalyzed by phase I (cytochrome P450; CYP) and phase
II (UDP-glucuronosyltransferases, sulfotransferases)
metabolizing enzymes [4]. In humans, the parent com-
pound is largely metabolized into N-desmethyltamoxifen,
and to a lesser extent into active 4-hydroxytamoxifen.
Both metabolites can be further metabolized into 4-hy-
droxy-N-desmethyltamoxifen (endoxifen), which is
thought to be the pharmacologically most important
metabolite as it has a higher estrogen receptor affinity
than the mother compound and reaches higher systemic
levels than 4-hydroxytamoxifen [4, 5]. Several CYP
enzymes are involved in the metabolism of tamoxifen,
including CYP2D6, CYP3A4, CYP2C9, and CYP2C19,
of which CYP2D6 is the main enzyme for endoxifen
formation. Tamoxifen and its metabolites are subse-
quently metabolized into other phase I metabolites and
conjugates and eliminated through the bile, feces, and
urine [4, 6].
Endoxifen is considered to be responsible for the clinical
effects of tamoxifen therapy. As recently suggested, a mini-
mum threshold concentration for endoxifen should be attained
to benefit from tamoxifen therapy [7]. Reduced endoxifen
formation has been observed in tamoxifen-treated individuals
carrying CYP2D6 variant alleles and with the concomitant
use of CYP2D6-inhibiting medications [8]. Both factors have
also been associated with clinical outcome in tamoxifen-
treated breast cancer patients, although the results of these
studies have been inconsistent [9–12]. However, endoxifen
formation not only depends on CYP2D6, as other enzymes,
including CYP3A4 and CYP2C9, appear to be important as
well. CYP3A4*22 genotype and concomitant medication that
alters CYP3A4 enzyme activity have both been shown to
affect tamoxifen pharmacokinetics [13, 14]. In addition to
these factors, which contribute to inter-individual pharma-
cokinetic variability, tamoxifen pharmacokinetics may also
differ within patients, known as intra-individual variability. In
this way, circadian rhythms may influence tamoxifen
pharmacokinetics.
Many biochemical and physiological processes in
organisms, including animals and humans, follow
day–night rhythms. These daily rhythms are generated
by an internal timing system known as the circadian
clock. Circadian variations in gastrointestinal func-
tions, hepatic and intestinal enzyme activity and
organ blood flow may all affect absorption, distribu-
tion, metabolism, and elimination of drugs,
including tamoxifen. Accordingly, depending on the
time of drug administration, endoxifen concentrations
may vary, which is possibly important for the efficacy
of tamoxifen therapy and occurrence of adverse
effects [15–17].
Here, we investigated circadian variation in the phar-
macokinetics of tamoxifen in mice and breast cancer
patients. Circadian changes in plasma and organ exposure
to tamoxifen and its metabolites were studied in FVB mice,
which were orally administered tamoxifen at six different
times over a 24-h period. Additionally, we examined cir-
cadian rhythms in mRNA levels of essential CYP enzymes
in tissues of FVB mice. To evaluate circadian variation in
pharmacokinetics of tamoxifen in breast cancer patients,
we examined three different administration times: morning
(8 a.m.), afternoon (1 p.m.), and evening (8 p.m.).
Methods
Animals and synchronization
One-hundred twenty-six female FVB mice with an age of
8–12 weeks were used in the experiments. Animals were
housed under standardized conditions with a room tem-
perature of 22 C, relative humidity of 55 %, and food and
water ad libitum. For logistic reasons, the mice were kept
in two rooms, under either a normal or inverted 12 h light/
12 h dark regime (light 8 a.m.–8 p.m. and dark 8 p.m.–8
a.m. and vice versa). The animal experiments were
approved by DEC consult, an independent Animal Ethical
Committee (Dutch equivalent of the IACUC) and per-
formed in accordance with local guidelines.
Study in mice
Tamoxifen was dissolved in peanut oil at a concentration
of 4 mg/ml, which was freshly prepared before each
administration time. At six different time points, at 8
a.m., noon, 4 p.m., 8 p.m., midnight, and 4 a.m. (taking
into account normal and inverted light/dark regimes), a
fixed dose of 4 mg tamoxifen (*200 mg/kg bodyweight)
was administered orally by gavage into the stomach to a
group of 18 mice. Mice were fasted for 3 h prior to
tamoxifen administration to minimize variation in
absorption. Under anesthesia with isoflurane, blood sam-
ples were collected from the orbital sinus at 1, 2, 3, 5, 10,
and 20 h after tamoxifen administration. Three mice were
sacrificed per time point. After cervical dislocation, liver
and small intestine (proximal, middle, and distal part)
were quickly removed. Sample preparation and storage
and pharmacokinetic analysis are described in the Sup-
plementary Material.
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In a control group of 18 mice, administered solvent
orally by gavage, plasma, liver and small intestine samples
were collected every 4 h in a 24-h period (3 mice/time
point). Rhythmic mRNA expression of CYP enzymes was
examined in mouse liver and three consecutive parts of the
small intestine (see Supplementary Material). Expression
of components of the circadian clock [Period 2 (Per2),
Dbp, Bmal1, Cryptogene 1 (Cry1) and Rev-erb-a] was also
determined, indicating the proper light entrainment of the
mice.
Patients
Women using tamoxifen for breast cancer once daily for at
least 4 months (to guarantee steady state) were included in
the study. Additional eligibility criteria included age
[18 years, WHO performance score B1, normal blood cell
counts, and adequate renal and hepatic functions. The use of
(herbal) supplements was not allowed during the whole
study period. During clinical days, patients received stan-
dard hospital meals, served at 7.30 a.m., noon, and 5 p.m.
The study was performed at the Erasmus MC Cancer
Institute, Rotterdam, The Netherlands. The Local Ethics
Committee approved the study protocol (Dutch Trial Reg-
istry; NTR3473) and the study was conducted in accordance
with the Declaration of Helsinki. All participants provided
written informed consent before study entry.
Clinical study
This was a pharmacokinetic cross-over study, analyzing up
to three different dosing times of tamoxifen. At the start of
the study, patients were using tamoxifen once daily at an
oral dose of 20 or 40 mg either in the morning or evening.
Due to the prolonged period for reaching steady state levels
of tamoxifen metabolites, randomization was impractical,
and patients were allocated to one of the two sequences
(starting in morning or evening), depending on the time of
tamoxifen administration before the study. After at least
4 weeks of dosing at either 8 a.m. or 8 p.m., pharmacoki-
netic profiles of tamoxifen and its metabolites were assessed
during a 24-h period. Patients were then switched to the
other time of administration for at least 4 weeks followed
by a second pharmacokinetic blood sampling period. The
third time of pharmacokinetic blood sampling occurred
after 4 weeks of tamoxifen dosing in the afternoon (1 p.m.).
On each study day, blood samples for hematological and
biochemical analysis were also obtained. In addition,
information on adherence, dosing time, concomitant med-
ication, and adverse effects was collected on the days of
pharmacokinetic blood sampling. Blood sample collection,
measurement of tamoxifen and its metabolites in plasma
[18], calculation of pharmacokinetic parameters,
genotyping, and statistical analysis were performed as
described in the Supplementary Material.
Results
Study in mice
To evaluate potential circadian rhythms in CYP-mediated
metabolism and the contribution to circadian variation in
pharmacokinetics of tamoxifen, mRNA expression levels
of CYP enzymes involved in the metabolism of tamoxifen
were assessed in tissues of mice over a 24-h period. The
daily mRNA expression patterns of components of the
circadian clock [Period 2 (Per2), Dbp, Bmal1, Cryptogene
1 (Cry1) and Rev-erb-a], and drug-metabolizing enzymes
(Cyp2d10, Cyp2d22 and Cyp3a11; orthologues of human
CYP enzymes involved in tamoxifen metabolism) in
mouse liver and small intestine (control group) are dis-
played in Supplementary Fig. 1. As expected, cosinor
analysis, used for the evaluation of 24-h rhythmicity,
showed circadian oscillation in mRNA expression of
components of the circadian clock. According to cosinor
analysis, the mRNA expression of Cyp2d10 and Cyp2d22
in mouse liver appeared to oscillate rhythmically with a
period of 24 h (P B 0.0413). Highest expression levels of
Cyp2d10 and CYP2d22 were observed at 4 a.m. (which was
the active phase of the mice in the experiment) and lowest
at 4 p.m. (resting phase), with peak–trough ratios of 1.5 and
2.9. Expression of Cyp3a11 mRNA showed 24-h variation
in the proximal part of the small intestine in mice
(P = 0.0172), and transcript levels peaked at midnight and
were lowest at noon (peak–trough ratio 2.8).
We then examined circadian variation in plasma and
organ exposure to tamoxifen and its metabolites in mice.
The exposure to tamoxifen and its metabolites 4-hydrox-
ytamoxifen (major metabolite in mice), N-desmethylta-
moxifen and endoxifen in plasma, liver, and three
consecutive parts of the small intestine for the six dosing
time groups are presented in Supplementary Table 1. Mean
plasma concentration–time curves for tamoxifen following
six administration times are displayed in Fig. 1.
In mice, no significant differences in exposure to
tamoxifen and its metabolites were observed in plasma or
tissues after oral tamoxifen administration at six different
time points in a 24-h period. Cosinor analysis did not show
significant circadian rhythms in area under the curves
(AUCs) of the compounds as a function of dosing time
(P C 0.1354). A 12-h rhythm was also not found. However,
although not statistically significant, a trend towards higher
tamoxifen exposure in plasma and liver tissue, expressed as
AUC0–last, was seen following administration at midnight,
which is the period in which mice are most active (Fig. 2).
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Clinical study
Twenty-seven women with hormone receptor-positive
breast cancer completed two study periods: administration
of tamoxifen in the morning (8 a.m.) and in the evening (8
p.m.). Of these patients, 12 women completed the third
period of tamoxifen administration in the afternoon (1
p.m.). Before study entry, tamoxifen was used by 17
women in the morning (63 %), and by 10 women in the
evening (37 %). Twenty-six patients received tamoxifen at
a single dose of 20 mg; one woman received 40 mg for
metastatic disease. The mean age of the study participants
was 53 ± 9 years, and the mean BMI was 27.5 ± 4.7 kg/
m2.
Adverse events observed in this study included hot fla-
shes (n = 25), mood swings (n = 5), joint pain (n = 5),
and weight gain (n = 3), which are all known side effects
of tamoxifen. No serious adverse events occurred during
the study period. Hematological and biochemical parame-
ters were not statistically or clinically relevant different
between the days of pharmacokinetic blood collection and
none of the patients showed signs of disturbed liver or
kidney function.
Concerning differences between morning and evening
administration (n = 27), the mean plasma concentration–
time profiles and pharmacokinetic parameters for tamox-
ifen and its metabolites are presented in Fig. 3 and Table 1,
respectively. Small but significant differences were
observed in pharmacokinetic parameters of tamoxifen and
its three major metabolites between morning and evening
administration. For tamoxifen, the AUC0–8 h and Cmax
were 20 % (P\ 0.001) higher, and tmax was shorter after
administration in the morning compared to evening dosing.
Other pharmacokinetic parameters did not significantly
differ between morning and evening administration. For
endoxifen, the AUC0–8 h and Cmax were both 23 % higher
(P\ 0.001) following morning administration compared
to evening administration. However, the difference in the
AUC0–24 h was small [15 % (P\ 0.001)].
The metabolic ratios, endoxifen-to-N-desmethyltamox-
ifen, N-desmethyltamoxifen-to-tamoxifen, 4-hydroxyta-
moxifen-to-tamoxifen, and total metabolites-to-tamoxifen
differed only 6–9 % between morning and evening
administration.
In the subgroup of women who completed three periods
of different administration times (n = 12), no significant
differences in pharmacokinetic parameters or metabolic
ratios for tamoxifen and its metabolites were observed
between dosing in the afternoon versus morning or dosing
in the afternoon versus evening (Fig. 4; Supplementary
Table 2).
Results of genotyping for CYP polymorphisms are
summarized in Table 2. Endoxifen systemic exposure was
relatively low in women who were CYP2D6 poor metabo-
lizer. Differences in endoxifen concentrations between
morning and evening administration seemed to be greater in
women having extensive CYP2D6 metabolism compared
with women having decreased CYP2D6 metabolism. The
effects of administration time on plasma concentrations of
Fig. 1 Plasma concentration–time curves of tamoxifen following
drug administration at six different times in a 24-h period in mice.
Tamoxifen was administered to mice at a dose of 4 mg by gavage at
six different time points. Blood samples were collected at 1, 2, 3, 5,
10, and 20 h after tamoxifen administration (3 mice/time point)
Fig. 2 Exposure to tamoxifen (AUC0–last) in plasma and liver tissue
of mice following tamoxifen administration at six different times.
Tamoxifen was administered to 18 mice at six different time points.
Blood was collected at six time points (3 mice/time point) after
tamoxifen administration and area under the curves (AUCs0–last) was
calculated. Data are presented as AUC0–inf (y-axis), derived from non-
compartmental analysis on plasma concentration–time profiles of
tamoxifen following dosing at six different times in a 24-h period (x-
axis)
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endoxifen or other metabolites did not vary according to
CYP2C19 or CYP3A4 genotypes. However, the sample size
was too small to detect differences between individuals with
different genotypes.
Discussion
In the preclinical study, circadian variation in mRNA
expression levels of CYP enzymes, Cyp2d10, Cyp2d22, and
Cyp3a11, in mouse liver, and small intestine was observed,
which is in accordance with the findings by Zhang et al.
[19]. On the basis of mRNA expression levels, higher CYP
enzyme activity could be expected during the active phase
and lower activity during the resting phase.
We observed that exposure to tamoxifen appeared to be
higher in mouse plasma and liver tissue after tamoxifen
administration in the active phase, with the highest levels
following administration at midnight, although differences
were not statistically significant. However, a large variation
in concentrations of tamoxifen and its metabolites between
the individual mice was observed, which may be explained
Fig. 3 Mean plasma
concentration–time profiles for
tamoxifen (a), endoxifen (b), N-
desmethyltamoxifen (c), and
4-hydroxytamoxifen
(d) following tamoxifen
administration in the morning at
8 a.m. (open circles) and in the
evening at 8 p.m. (closed
circles) in 27 women with (a
history) of breast cancer
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by several factors. First, the animals were given a fixed
dose of 4 mg tamoxifen and small differences in body-
weight of the mice may have contributed to the variability
in pharmacokinetics. In addition, tamoxifen was dissolved
in peanut oil and given by oral gavage, which also may
have influenced the absorption in mice.
In the exploratory clinical study, the pharmacokinetic
parameters of tamoxifen and its metabolites differed
slightly between morning and evening administration. The
tamoxifen Cmax and AUC0–8 h were both higher after
morning administration and tmax was reached earlier, sug-
gesting an increased absorption rate following morning
dosing compared with evening dosing. These results
complement previous findings of more rapid absorption of
lipophilic drugs after administration in the morning [15].
The underlying mechanisms of a higher absorption rate in
the early morning involve faster gastric emptying, higher
gastrointestinal motility, and higher gastrointestinal blood
Table 1 Pharmacokinetic parameters for tamoxifen and its metabolites following administration in the morning (8 a.m.) and evening (8 p.m.) in
27 women
Morning
administration
(8 a.m.)
Evening
administration
(8 p.m.)
Ratio
Morning versus
evening
Difference (95 %
confidence
interval)
P valuec
Tamoxifen
AUC0–8 h (nmol/l h) 2355 ± 709 1977 ± 587 1.20 ± 0.16 378 (273, 484) \0.001
AUC0–24 h (nmol/l h) 6266 ± 1853 6138 ± 1764 1.03 ± 0.11 128 (-133, 389) 0.324
C24 h (nmol/l) 246 ± 88.5 240 ± 75.1 1.04 ± 0.21 6.60 (-12.8, 26.0) 0.491
Cmax (nmol/l) 356 ± 107 298 ± 84.2 1.20 ± 0.20 58.0 (38.1, 77.8) \0.001
tmax (h) 2.1 (1.0–24.0) 8.1 (1.5–24.0) 0.001
t1/2 (h)
a 48.0 ± 32.3 76.3 ± 51.0 0.86 ± 0.64 -28.4 (-58.1, 1.36) 0.060
CL/F (l/h) 9.40 ± 3.17 9.55 ± 3.04 0.99 ± 0.11 -0.16 (-0.59, 0.28) 0.471
ND-tamoxifen
AUC0–8 h (nmol/l h) 4081 ± 1576 3496 ± 1263 1.16 ± 0.13 584 (400, 768) \0.001
AUC0–24 h (nmol/l h) 11,891 ± 4280 11,092 ± 4017 1.08 ± 0.13 799 (316, 1283) 0.002
C24 h (nmol/l) 519 ± 210 476 ± 176 1.09 ± 0.17 43.5 (8.99, 78.0) 0.015
Cmax (nmol/l) 615 ± 235 536 ± 207 1.16 ± 0.19 78.9 (44.9, 113) \0.001
tmax (h) 2.1 (0.5–24.2) 4.1 (0.5–24.2) 0.019
4OH-tamoxifen
AUC0–8 h (nmol/l h) 35.6 ± 10.6 28.6 ± 9.20 1.28 ± 0.30 7.01 (4.85, 9.19) \0.001
AUC0–24 h (nmol/l h) 101 ± 30.0 92.8 ± 30.6 1.12 ± 0.24 8.50 (3.18, 13.83) 0.003
C24 h (nmol/l) 4.24 ± 1.24 3.86 ± 1.35 1.14 ± 0.24 0.37 (0.10, 0.65) 0.010
Cmax (nmol/l) 5.26 ± 1.63 4.43 ± 1.48 1.25 ± 0.49 0.823 (0.356, 1.29) 0.001
tmax (h) 4.0 (0.5–24.0) 12.0 (1.0–24.1) 0.001
Endoxifen
AUC0–8 h (nmol/l h) 179 ± 84.3 144 ± 61.9 1.23 ± 0.14 34.9 (23.4, 46.4) \0.001
AUC0–24 h (nmol/l h) 524 ± 245 453 ± 203 1.15 ± 0.13 70.6 (45.4, 95.7) \0.001
C24 h (nmol/l) 22.5 ± 10.2 19.7 ± 9.05 1.16 ± 0.20 2.74 (1.41, 4.08) \0.001
Cmax (nmol/l) 27.2 ± 12.5 22.0 ± 9.27 1.23 ± 0.21 5.20 (3.20, 7.19) \0.001
tmax (h) 2.1 (0.5–24.2) 4.1 (0.5–24.2) 0.026
Metabolic ratio
Metab/tamoxifenb 2.01 ± 0.33 1.90 ± 0.32 1.06 ± 0.078 0.11 (0.053, 0.16) \0.001
Data are presented as mean and standard deviation. tmax expressed as median and range. Parameters of one patient using 40 mg tamoxifen were
dose-corrected to 20 mg
ND-tam N-desmethyltamoxifen, 4OH-tam 4-hydroxytamoxifen, Metab metabolites, AUC area under the curve, C24 h concentration before dosing
(t = 24 h); Cmax maximum concentration, tmax time to reach Cmax, t1/2 elimination half-life, CL/F apparent oral clearance
a Based on results of 19 patients
b AUC0–24 h ratio of ND-tamoxifen, 4-OH-tamoxifen, and endoxifen–tamoxifen
c Paired Student’s t-test (tmax Wilcoxon signed-rank test)
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flow in the morning than in the evening [20–22]. In addi-
tion, since higher gastric acidity lowers lipophilic drug
absorption, the absorption of these drugs is generally lower
in the evening due to increased gastric acid secretion at that
moment of the day [23].
Slightly higher Cmax and AUC0–8 h values and shorter
tmax were also observed for the metabolites following
morning dosing compared with evening dosing. The
endoxifen AUC0–24 h was also significantly higher fol-
lowing morning dosing than following evening dosing;
however, the actual difference was only minor. Despite the
higher metabolite concentrations, the difference in meta-
bolic ratios of the three metabolites-to-tamoxifen between
morning and evening dosing was small and clinically
irrelevant (*6 %), implying that the increase in metabolite
concentrations is not associated with major changes in
CYP-mediated metabolism. The higher tamoxifen con-
centrations due to increased absorption in the early morn-
ing have probably contributed to the slightly higher
metabolite levels.
In the subgroup of 12 women who completed three cycles
of different dosing times, no relevant differences in phar-
macokinetic parameters of tamoxifen and its metabolites
were observed after drug administration in the afternoon
compared with administration in the morning or evening.
However, it seemed that the plasma exposure to tamoxifen
Fig. 4 Individual changes in
plasma exposure (AUC0–24 h)
and maximum concentrations
(Cmax) for tamoxifen (a, b) and
endoxifen (c, d) after tamoxifen
administration at three different
times; morning (8 a.m.),
afternoon (1 p.m.), and evening
(8 p.m.) in 12 women. For two
patients, AUC0–24 h data (1
p.m.) were lacking
Table 2 Results of genotyping for cytochrome P450 polymorphisms
Genes Alleles Number (%)a
CYP2D6 EM 15 (58)
IM 8 (31)
PM 3 (11)
CYP2C19 *1/*1 13 (50)
*1/*2 6 (23)
*1/*17 2 (8)
*2/*2 1 (4)
*2/*17 4 (15)
CYP3A4 *1/*1 10 (39)
*1/*22 12 (46)
*22/*22 4 (15)
EM two active alleles, IM one non-functional allele or two decreased
function alleles, PM two non-functional alleles
a Results of one individual were missing
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and its three metabolites following administration in the
afternoon was slightly higher than that observed after eve-
ning dosing but a little lower than after morning adminis-
tration. This may be explained by the fact that the sleep/
wakefulness cycle is the most important rhythm in humans
and influences physiological functions [16]. Therefore, the
greatest variation in processes, such as gastric emptying,
gastrointestinal motility, and gastric acid secretion, could be
expected between morning and evening.
In the preclinical study, plasma and liver exposure to
tamoxifen appeared to be highest following administration
at midnight. The results are in line with the observation of
higher plasma levels of tamoxifen after dosing at 8 a.m., the
start of the active phase in humans. However, in humans,
dosing in the afternoon did not result in the highest exposure
to tamoxifen and its metabolites. Differences in physio-
logical processes between mice and humans may be a
plausible explanation for this discrepancy. In addition, we
observed circadian variation in mRNA expression levels of
CYP enzymes in mouse liver and intestine. Circadian
variation of hepatic CYP3A4 activity in humans has been
assumed from the observation of a 2.8-fold mean diurnal
variation in the 6b-hydroxycortisol-to-cortisol ratio as a
marker of CYP3A4 activity [24]. Although differences in
tamoxifen pharmacokinetics in humans are probably due to
variation in absorption, the influence of circadian variation
in metabolism cannot be totally excluded. Metabolic ratios
did not show relevant differences between morning and
evening dosing; however, this might be explained by cir-
cadian variation in elimination of tamoxifen metabolites
through glucuronidation by UDP-glucuronosyltransferases
[25]. However, we did not measure glucuronides of
tamoxifen and its metabolites. A trend towards greater
differences in endoxifen exposure between morning and
evening administration in women with extensive CYP2D6
metabolism, according to genotype, was observed, which
might suggest a possible influence of circadian variation in
(CYP2D6) metabolism.
The study was not designed to detect potential differ-
ences in efficacy of tamoxifen treatment or side effects
between the different administration times. However, the
small changes in tamoxifen pharmacokinetics between
morning and evening administration are likely not relevant
for the efficacy of tamoxifen. A number of women reported
changes in incidence and severity of hot flashes during the
study, which may indicate a possible relation between the
time of tamoxifen administration and occurrence of hot
flashes. Possibly, the occurrence of hot flashes is associated
with peak plasma concentrations of tamoxifen or one of its
metabolites [26]. However, this could not be established in
this study.
Although to a lesser degree than other factors (i.e.,
CYP2D6 genetic polymorphisms, co-medication), circadian
rhythms contribute to interpatient and intrapatient phar-
macokinetic variability of tamoxifen. Therefore, dosing
time may be relevant in clinical studies and possibly for
applying therapeutic drug monitoring, which has been
proposed for individualization of tamoxifen therapy [27]. In
the last years, many studies have been undertaken to iden-
tify genetic and environmental factors which may con-
tribute to the inter-individual variability in
pharmacokinetics [4, 8, 13]. Currently, the majority of
studies focus on the relationship between CYP2D6 geno-
type, endoxifen concentrations, and clinical outcome or
toxicity [7, 28]. However, most studies do not take into
account the time of tamoxifen administration and the time
of blood collection (intra-individual circadian variation),
which may contribute to increased variability. Trough
samples are not always collected [7, 8], as the long elimi-
nation half-life of tamoxifen and N-desmethyltamoxifen
suggest no large differences in concentrations. However,
the results of this study suggest that the time of tamoxifen
administration as well as sampling time may be relevant and
should be taken into consideration in studies relating
endoxifen concentrations and clinical outcome.
Potential limitations of our study include the lack of
standardization of waking and sleeping hours of the study
participants and standardization of the meals. Although the
meals were not strictly controlled, it is unlikely that this
may have influenced the results of the study given that food
has not been shown to affect the pharmacokinetics of
tamoxifen [29]. In addition, meals were served on fixed
times (at 7.30 a.m., noon, and 5 p.m.), with the time of
dinner in the evening 3 h before tamoxifen administration,
making the influence of food on the pharmacokinetics even
more unlikely.
Conclusions
The present study shows that differences in dosing time (i.e.,
morning vs. evening) lead to small differences in tamoxifen
pharmacokinetics, probably not relevant for the efficacy of
the drug. To minimize additional interpatient and intrapa-
tient pharmacokinetic variability, administration time
should be taken into consideration in studies relating
endoxifen concentrations and clinical outcome and possibly
in therapeutic drug monitoring for therapy individualization.
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